INTERFERON (IFN)-FREE TREATMENT WITH ONCE-DAILY ALISPORIVIR (ALV) ACHIEVES AND MAINTAINS HIGH RATES OF UNDETECTABLE HCV RNA IN A GLOBAL POPULATION OF TREATMENT-NAIVE PATIENTS WITH HCV GENOTYPE (G) 2 OR 3 (VITAL-1 STUDY)

Conference Reports for NATAP

Presented at the 22nd Conference of the Asian Pacific Association for the Study of the Liver (APASL)
Taipei, Taiwan
February 16-19, 2012


INTERFERON (IFN)-FREE TREATMENT WITH ONCE-DAILY ALISPORIVIR (ALV) ACHIEVES AND MAINTAINS HIGH RATES OF UNDETECTABLE HCV RNA IN A GLOBAL POPULATION OF TREATMENT-NAIVE PATIENTS WITH HCV GENOTYPE (G) 2 OR 3 (VITAL-1 STUDY)

	Reported by Jules Levin Presented at APASL 2012; 16-19 February 2012; Taipei, Taiwan ROC SK SARIN,1 T PIRATVISUTH,2 WL CHUANG,3 JM PAWLOTSKY,4 R FLISIAK,5 J RASENACK,6 GR FOSTER,7 H WEDEMEYER,8 W ZHANG,9 C AVILA10 1DEPT OF HEPATOLOGY, INSTITUTE OF LIVER AND BILIARY SCIENCES (ILBS), NEW DELHI, INDIA; 2NKC INSTITUTE OF GASTROENTEROLOGY AND HEPATOLOGY, SONGKLANAGARIND HOSPITAL, PRINCE OF SONGKLA HAT YAI, THAILAND; 3KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL, KAOHSIUNG MEDICAL UNIVERSITY, KAOHSIUNG, TAIWAN; 4UNIVERSITY HOPITAL HENRI MONDOR, CRETEIL, FRANCE; 5MEDICAL UNIVERSITY, BIAYSTOK, POLAND; 6ALBERT LUDWIGS UNIVERSITY, FREIBURG, GERMANY; 7QUEEN MARY, UNIVERSITY OF LONDON, BART'S AND THE LONDON SCHOOL OF MEDICINE, UK; 8DEPT OF GASTROENTEROLOGY, HEPATOLOGY AND ENDOCRINOLOGY, MEDIZINISCHE HOCHSCHULE HANNOVER, HANNOVER, GERMANY; 9BEIJING NOVARTIS PHARMA CO LTD, SHANGHAI, CHINA; 10NOVARTIS PHARMA AG, BASEL, SWITZERLAND